Loading...
XSTO
QLINEA
Market cap11mUSD
Oct 09, Last price  
16.85SEK
1D
-0.59%
1Q
-2.60%
IPO
-74.47%
Name

Q linea AB

Chart & performance

D1W1MN
XSTO:QLINEA chart
P/E
—
P/S
10.11
EPS
—
Div yield, %
—
Shrs. gr., 5y
-23.43%
Rev. gr., 5y
114.75%
Revenues
11m
+369.86%
81,0001,500,0001,066,0001,005,000243,0009,335,00012,788,0004,440,0002,362,00011,098,000
Net income
-182m
L-15.86%
-60,091,000-67,879,000-128,353,000-178,060,000-220,191,000-233,183,000-275,770,000-229,366,000-216,871,000-182,485,000
CFO
-162m
L-11.17%
-52,834,000-62,865,000-122,712,000-169,760,000-237,305,000-255,050,000-250,863,000-228,521,000-182,495,000-162,119,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

Related entities

Parent (2)
Nexttobe AB
Dimio Holding Limited

Key people

Erika Kjellberg Eriksson
Chairman of the Board · since 2018
Chief Executive Officer · since 2008
Nils Kristensen
Chief Operating Officer · since 2017
Mats Gullberg
Vice President, Research Director · since 2017
Charlotta Goransson
Marketing Director · since 2017
Tiziana Di Martino
Chief Medical Officer · since 2019
Thomas Fritz
Chief Commercial Officer · since 2019
Jonas Melin
Director Product Development · since 2017
IPO date
Dec 07, 2018
Employees
149
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Dag Hammarskjölds väg 52A
Uppsala 752 37
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT